Table 3.
Patient Demographics After Propensity Score Matching (n=3,296)
| Characteristic | Surgical Volume |
P | Standardized Difference | |
|---|---|---|---|---|
| High (n=1,648) | Mid and Low (n=1,648) | |||
|
| ||||
| Age (y) | 47.2±11.7 | 47.2±12.4 | .930 | .003 |
| Year | .300 | .033 | ||
| 2004 | 349 (21.2) | 311 (18.9) | ||
| 2005 | 323 (19.6) | 318 (19.3) | ||
| 2006 | 328 (19.9) | 366 (22.2) | ||
| 2007 | 327 (19.8) | 343 (20.8) | ||
| 2008 | 321 (19.5) | 310 (18.8) | ||
| Clinical stage | .337 | .042 | ||
| IB1 | 931 (56.5) | 883 (53.6) | ||
| IB2 | 266 (16.1) | 297 (18.0) | ||
| IIA | 141 (8.6) | 142 (8.6) | ||
| IIB | 310 (18.8) | 326 (19.8) | ||
| Histology | .898 | .015 | ||
| Squamous | 1,066 (64.7) | 1,069 (64.9) | ||
| Adenocarcinoma | 399 (24.2) | 408 (24.8) | ||
| Adenosquamous | 162 (9.8) | 153 (9.3) | ||
| Others | 21 (1.3) | 18 (1.1) | ||
| Parametrial involvement | .733 | .059 | ||
| No | 1,317 (79.9) | 1,324 (80.4) | ||
| Yes | 331 (20.1) | 323 (19.6) | ||
| Node metastasis (pelvic) | .166 | .049 | ||
| No | 1,186 (72.3) | 1,210 (74.5) | ||
| Yes | 454 (27.7) | 415 (25.5) | ||
| Node metastasis (para-aortic) | .246 | .042 | ||
| No | 217 (14.1) | 241 (15.9) | ||
| Yes | 39 (2.5) | 30 (2.0) | ||
| Not examined* | 1,279 (83.3) | 1,243 (82.1) | ||
| Deep stromal invasion | .662 | .012 | ||
| No | 621 (43.2) | 683 (44.0) | ||
| Yes | 817 (56.8) | 870 (56.0) | ||
| Tumor size (cm) | .104 | .016 | ||
| 4 or less | 1,055 (70.1) | 1,015 (67.4) | ||
| More than 4 | 449 (29.9) | 491 (32.6) | ||
| LVSI | .404 | .030 | ||
| No | 676 (42.5) | 647 (41.1) | ||
| Yes | 913 (57.5) | 928 (58.9) | ||
| Uterine corpus invasion | .175 | .048 | ||
| No | 1,304 (83.6) | 1,379 (85.3) | ||
| Yes | 256 (16.4) | 237 (14.7) | ||
| Ovarian metastasis | .926 | .003 | ||
| No | 1,464 (98.6) | 1,559 (98.5) | ||
| Yes | 21 (1.4) | 23 (1.5) | ||
| Peritoneal cytology | .775 | .015 | ||
| No malignant cells | 458 (27.8) | 436 (26.7) | ||
| Malignant cells | 33 (2.0) | 33 (2.0) | ||
| Not examined* | 1,157 (70.2) | 1,165 (71.3) | ||
| Neoadjuvant chemotherapy | .385 | .025 | ||
| No | 1,353 (83.2) | 1,340 (82.1) | ||
| Yes | 273 (16.8) | 293 (17.9) | ||
| Adjuvant therapy | .630 | .030 | ||
| None | 675 (41.7) | 640 (40.9) | ||
| Radiotherapy alone | 294 (18.1) | 282 (18.0) | ||
| CCRT | 340 (21.0) | 352 (22.5) | ||
| Chemotherapy alone | 302 (18.6) | 277 (17.7) | ||
| Combined† | 9 (0.6) | 14 (0.9) | ||
LVSI, lymphovascular space invasion; CCRT, concurrent chemoradiotherapy.
Data are mean±SD or n (% per column) unless otherwise specified.
Binary logistic regression test was used for P-value.
A standardized difference of 0.10 or less indicates a good balance between the two groups.
*
Histologically assessed.
†
Both systemic chemotherapy and radiotherapy. Total number may not be 3,296 owing to missing data.